December 01, 2020
Article
The agency approved the first PSMA-targeted PET imaging drug for men with prostate cancer.
October 27, 2020
EMPIRE-1 is the first randomized trial to demonstrate an improvement in failure-free survival with treatment based on advanced molecular imaging versus conventional imaging in men with recurrent prostate cancer.
October 22, 2020
The imaging modality detected nodal metastasis with a sensitivity of 55.3% and a specificity of 84.8% in each patient.
